ArticleBMC neurology2026
Correlations of thrombus MMP-9 level with clinical characteristics and inflammatory markers in acute ischemic stroke.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveTo investigate the associations between thrombus Matrix Metalloproteinase-9 (MMP-9) level and the systemic inflammatory characteristics in patients with Acute Ischemic Stroke (AIS), and to evaluate the value of thrombus MMP-9 as a prognostic indicator of AIS.
methodsThis study enrolled 31 patients with AIS according to both clinical and imaging diagnostic criteria. All patients underwent mechanical thrombectomy within 24 h of symptom onset. The demographic data and basic clinical information were recorded. Mean optical density (MOD) of MMP-9 in thrombi and serum inflammatory markers were measured. Correlation between thrombus MMP-9 MOD and serum inflammatory markers was analyzed. Independent risk factors for long-term prognosis were identified using multivariate logistic regression. The predictive value of thrombus MMP-9 for AIS outcomes was assessed via ROC curve analysis.
resultsMOD of thrombus MMP-9 was significantly correlated with peripheral blood neutrophil-to-lymphocyte ratio (NLR), absolute neutrophil count (ANC), C-reactive protein-to-albumin ratio (CAR), absolute lymphocyte count (ALC), and monocyte-to-lymphocyte ratio (MLR). Patients with higher MMP-9 level exhibited significantly higher admission National Institutes of Health Stroke Scale (NIHSS) scores, 90-day modified Rankin Scale (mRS) scores, incidence of hemorrhagic transformation (HT), and pneumonia rate compared to those with lower MMP-9 level. Patients with poor outcomes had higher thrombus MMP-9 level, higher prevalence of hypertension, more thrombectomy device passes, longer puncture-to-recanalization time, higher HT rates, higher admission NIHSS scores, higher NLR, higher MLR, and higher pneumonia incidence, but lower rates of successful recanalization after the first thrombectomy pass. Furthermore, higher thrombus MMP-9 level may serve as an independent risk factor for poor 3-month functional outcomes. ROC analysis showed that thrombus MMP-9 was associated with poor outcomes with an area under the curve (AUC) of 0.915 (sensitivity 87.1%, specificity 87.5%).
conclusionHigh thrombus MMP-9 level correlates with systemic inflammatory markers, clinical severity, 3-month poor outcomes, and incidence of complications (including HT and pneumonia). These findings suggest thrombus MMP-9 may serve as a potential prognostic biomarker; however, larger multicenter studies are required for validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.